Cabazitaxel in platinum refractory ovarian cancer. A phase II trial
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2014
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TaxOvar
- 03 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 11 Dec 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01747239).
- 11 Dec 2012 Planned End Date changed from 13 Feb 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.